Shan David
Known title: EVP and Chief ISC OfficerCIK: 0001963048
Associated companies
Transaction History
| BDX | ▼ Sell | Tax Withholding | 44 | $0 | 1/3/2026 | View on chart |
| BDX | ▲ Buy | Grant | 3,504 | $0 | 11/26/2025 | View on chart |
| BDX | ▲ Buy | Grant | 1,025 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 134 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 1,166 | $200K | 6/2/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 500 | $120K | 1/21/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 44 | $0 | 1/3/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 1,500 | $330K | 12/5/2024 | View on chart |
| BDX | ▲ Buy | Grant | 1,110 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 1,106 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 124 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 44 | $0 | 1/3/2024 | View on chart |
| BDX | ▲ Buy | Grant | 832 | $0 | 11/26/2023 | View on chart |
| BDX | ▲ Buy | Grant | 1,576 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 149 | $0 | 11/26/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.